University of Delhi
Interferon-alpha and lamivudine combination yields higher therapeutic efficacy
Published in Lab Business Week, December 25th, 2005
"Monotherapy with interferon (IFN) or lamivudine is effective in a limited proportion of CHB patients. A sequential combination may have better therapeutic effects by sustained viral suppression combined with immunomodulation," wrote S.K. Sarin and colleagues, University of Delhi.
"To compare the efficacy of sequential lamivudine and IFN therapy versus lamivudine monotherapy in HBeAg positive CHB patients, 75 treatment naive HBeAg positive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-12-25)
More Articles from Lab Business Week
- 3M
Drug delivery device maker amends zero coupon senior convertible notes - AXM Pharma, Inc.
Pharmaceutical firm focused on Asian markets reports $0.16 per share loss - Acadia Pharmaceuticals, Inc.
Neuroscience-focused pharmaceutical firm reports loss of $12.3M - American Oriental Bioengineering, Inc.
Chinese biotech firm's common stock approved for listing on the Archipelago Exchange - AmerisourceBergen Corp.
Pharmaceutical services company doubles quarterly dividend and splits stock two-for-one - Arius Research, Inc.
Cancer drug developer secures US$2M funding commitment - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
